CME Group markets open and trading following 10-hour outage
Investing.com - Stifel maintained its Buy rating and $58.00 price target on Celldex Therapeutics (NASDAQ:CLDX) following the company’s third-quarter 2025 update. Currently trading at $22.15, CLDX shows significant upside potential against Stifel’s target, with analyst consensus remaining bullish and the highest price target reaching $90. InvestingPro data indicates the company is slightly undervalued based on its Fair Value assessment.
The biopharmaceutical company continues to enroll patients in two Phase 3 trials for barzovolimab in chronic spontaneous urticaria (CSU), with primary completion expected by October 2026, aligning with management’s previous guidance for full enrollment by summer.
Celldex plans to begin enrolling patients in Phase 3 trials for cold urticaria (ColdU) and symptomatic dermatographism in December 2025, with Stifel viewing the overall Phase 3 program as "highly-derisked" based on strong efficacy data to date.
The research firm noted that recent launches of dupilumab and remibrutinab in urticaria represent "meaningful tailwinds for market expansion among derms," potentially benefiting Celldex’s market position.
Beyond urticaria, Celldex continues to enroll patients in Phase 2 proof-of-concept studies for atopic dermatitis and prurigo nodularis, with topline results expected in the second half of 2026, while its CDX-122 bispecific antibody program advances with a multiple ascending dose update anticipated in the third quarter of 2026.
In other recent news, Celldex Therapeutics Inc reported third-quarter earnings that did not meet analyst expectations. The company posted a loss of $1.01 per share for the quarter ending September 30, which was wider than the analyst consensus estimate of a $0.90 loss. This shortfall is attributed to increased research and development expenses, which rose to $62.9 million, compared to $45.3 million in the same period last year. Celldex reported no revenue for the quarter, as the company continues to focus on its pipeline of mast cell inhibitors, particularly barzolvolimab. The company’s financial performance reflects its ongoing investment in pipeline development. Despite the earnings miss, the stock remained flat following the announcement. These developments are part of Celldex’s broader strategy to advance its clinical-stage projects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.